Fact sheet: Doravirine (Pifeltro)


This fact sheet provides detailed information for patients about the non-nucleoside reverse transcriptase inhibitor (NNRTI) Doravirine (Pifeltro).

September 11, 2018
Year of publication
Resource types
Reports and Fact sheets
non-nucleoside reverse transcriptase inhibitor (NNRTI), antiretroviral drugs

Similar Resources

Access to clean water and basic toilets is an essential but neglected part of managing living with HIV, new research by international development organisations WaterAid and SAfAIDS has found.


To assess the design, delivery and outcomes of interventions to improve adherence to treatment for paediatric tuberculosis in low- and middle-income countries and develop a contextual framework for such interventions.


This supplement to Acta Paediatrica presents a series of meta-analyses and systematic literature reviews examining a variety of health effects potentially related to breastfeeding.

The Cochrane Library (ISSN 1465-1858) is a collection of six databases that contain different types of high-quality, independent evidence to inform healthcare decision-making, and a seventh database that provides information about Cochrane groups.

This issue of the Southern African HIV Clinicians Society's "HIV Nursing Matters" online magazine focuses on vulnerable populations, including TB in prisons and intimate partner violence in the context of HIV.

This issue of the Southern African HIV Clinicians Society's "HIV Nursing Matters" online magazine focuses on key populations.

Introduction: Cervical cancer is the second most common form of cancer for women in Ethiopia.

In chronic HIV infection, initiation of antiretroviral therapy (ART) typically induces swift HIV RNA declines and virologic suppression within 24 weeks.

Timely access to antiretroviral treatment (ART) is vital to ensuring safe motherhood and reducing vertical transmission. Treatment guidance and programming has changed dramatically in recent years.

This report describes the coalescence of the AIDS response and the broader global health and development field around the 90-90-90 target over the last two years.